1. Home
  2. TMC vs COAG Comparison

TMC vs COAG Comparison

Compare TMC & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TMC the metals company Inc.

TMC

TMC the metals company Inc.

BUY

Current Price

$2.45

Market Cap

2.1B

ML Signal

BUY

COAG

Hemab Therapeutics Holdings Inc. Common Stock

HOLD

Current Price

$34.35

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMC
COAG
Founded
2011
2020
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
TMC
COAG
Price
$2.45
$34.35
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$10.90
★ $62.67
AVG Volume (30 Days)
★ 4.5M
347.8K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 232.00
N/A
EPS
★ 0.19
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.08
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$27.38
52 Week High
$10.05
$55.42

Technical Indicators

Market Signals
Indicator
TMC
COAG
Relative Strength Index (RSI) 23.68 50.57
Support Level N/A $28.46
Resistance Level $4.81 $38.87
Average True Range (ATR) 0.19 2.56
MACD -0.05 1.02
Stochastic Oscillator 4.18 76.54

Price Performance

Historical Comparison
TMC
COAG

About TMC TMC the metals company Inc.

TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: